With potential $1.7 billion deal, Genentech kicks its cancer immunotherapy work into new gear

Genentech Inc. will pay $30 million upfront — and potentially $1.7 billion overall based on milestones — to work on a set of potential cancer immunotherapies with a British company. For Bicycle Therapeutics plc of Cambridge, England, and Lexington, Mass., the early discovery collaboration gives it a chance to show off its technology on m ore drugs that manipulate the immune system to spot and attack cancer cells. Specifically, Bicycle's appropriately named synthetic bicyclic peptides are designed…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news